PT - JOURNAL ARTICLE AU - Robert A. Lewis AU - Charlotte Durrington AU - Robin Condliffe AU - David G. Kiely TI - BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing? AID - 10.1183/16000617.0009-2020 DP - 2020 Jun 30 TA - European Respiratory Review PG - 200009 VI - 29 IP - 156 4099 - http://err.ersjournals.com/content/29/156/200009.short 4100 - http://err.ersjournals.com/content/29/156/200009.full SO - EUROPEAN RESPIRATORY REVIEW2020 Jun 30; 29 AB - Despite the advent of new therapies and improved outcomes in patients with pulmonary arterial hypertension (PAH), it remains a life-shortening disease and the time to diagnosis remains unchanged. Strategies to improve outcomes are therefore currently focused on earlier diagnosis and a treatment approach aimed at moving patients with PAH into a category of low-risk of 1-year mortality. B-type natriuretic peptide (BNP; or brain natriuretic peptide) and N-terminal prohormone of BNP (NT-proBNP) are released from cardiac myocytes in response to mechanical load and wall stress. Elevated levels of BNP and NT-proBNP are incorporated into several PAH risk stratification tools and screening algorithms to aid diagnosis of systemic sclerosis. We have undertaken a systematic review of the literature with respect to the use of BNP and NT-proBNP in PAH and the use of these biomarkers in the diagnosis and risk stratification of PAH, their relation to pulmonary haemodynamics and the potential for point-of-care testing to improve diagnosis and prognosis.Despite the widespread use of BNP and NT-proBNP in pulmonary arterial hypertension there are limited data on the standardisation of sampling and no data on the use of point-of-care testing and its potential value in clinical management https://bit.ly/2Xxm9uV